Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 L194F |
Therapy | Tanespimycin |
Indication/Tumor Type | breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 L194F | breast cancer | sensitive | Tanespimycin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011). | 26009011 |
PubMed Id | Reference Title | Details |
---|---|---|
(26009011) | Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. | Full reference... |